Washington – September 28, 2026 -- The U.S. Food and Drug Administration announced plans to evaluate changes to its application framework for new tobacco products, including e-cigarettes and nicotine pouches, aiming to simplify the pathway for these products to reach the market.
Truth Initiative warns weakened review could undermine public health protections
Kathy Crosby, CEO and President of Truth Initiative, said any changes that reduce the scientific evidence required or diminish the review process would compromise the FDA's regulatory role. The law currently requires the agency to assess a product's components, ingredients, toxicological profile and health impact, alongside risks and benefits to the broader population, including youth and non-users.
More than 24 million U.S. adults still smoke combustible cigarettes
Crosby noted the need for an off-ramp from combustible cigarettes, described as the leading cause of preventable disease and death. She said FDA-authorized alternatives may serve adults unwilling or unable to quit nicotine entirely, provided such products are thoroughly vetted for unforeseen health risks.
Nearly 7,500 illegal e-cigarette and nicotine pouch products circulate unchecked
Crosby identified the proliferation of noncompliant products as the primary obstacle to achieving regulatory objectives, stating that nearly 7,500 illegal e-cigarette and nicotine pouch products have entered the market by exploiting enforcement gaps. These products are marketed with largely untested ingredients, she said, exposing all consumers to risk regardless of any framework changes intended for companies operating within the regulatory system.
Flavor variety and higher nicotine strengths raise youth initiation concerns
Crosby cautioned that as the FDA considers a wider range of flavors and higher nicotine strengths, authorized products must not become an on-ramp for addiction among young people and nicotine-naïve individuals. She said the review process should prioritize ensuring the FDA has sufficient scientific information to determine whether products meet the public health standard, rather than accelerating the speed at which products move through review.